Importance Oral targeted therapies have advanced the treatment of chronic lymphocytic
leukemia (CLL). These therapies include Bruton tyrosine kinase inhibitors, used as
monotherapy, and the Bcl-2 inhibitor venetoclax, typically combined with the CD20
monoclonal antibody. Preclinical studies have shown synergy between Bruton tyrosine
kinase inhibitors and the Bcl-2 inhibitor venetoclax. Objective To examine the rate of
complete remission, complete remission with incomplete count recovery, and bone marrow …

PURPOSE CAPTIVATE (NCT02910583), a randomized phase II study, evaluates minimal
residual disease (MRD)-guided treatment discontinuation following completion of first-line
ibrutinib plus venetoclax treatment in patients with chronic lymphocytic leukemia (CLL).
METHODS Previously untreated CLL patients age< 70 years received three cycles of
ibrutinib and then 12 cycles of combined ibrutinib plus venetoclax. Patients in the MRD
cohort who met the stringent random assignment criteria for confirmed undetectable MRD …